Safety and Efficacy of Olverembatinib (HQP1351) Combined with Lisaftoclax (APG-2575) in Children and Adolescents with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (R/R Ph plus ALL): First Report from a Phase 1 Study

被引：0

作者：

Zhang, Jingliao ^{[1
]}

Wang, Junxia ^{[1
]}

Guo, Huanshan ^{[2
]}

Liu, Tianfeng ^{[1
]}

Zhang, Xiaoyan ^{[1
]}

Zhang, Ranran ^{[1
]}

Ruan, Min ^{[1
]}

Chang, Lixian ^{[3
]}

Liu, Xiaoming ^{[1
]}

Ren, Yuanyuan ^{[1
]}

Chen, Xia ^{[1
]}

Wang, Hengbang ^{[4
]}

Chen, Zi ^{[4
]}

Zhang, Yingchi ^{[3
]}

Chen, Yumei ^{[1
]}

Zhang, Li ^{[3
]}

Guo, Ye ^{[1
]}

Liu, Fang ^{[5
]}

Chen, Xiaojuan ^{[5
]}

Zou, Yao ^{[1
]}

Yang, Wenyu ^{[5
]}

Zhai, Yifan ^{[2
,4
]}

Zhu, Xiaofan ^{[1
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Inst Hematol & Blood Dis Hosp, Natl Clin Res Ctr Blood Dis,Haihe Lab Cell Ecosyst, Tianjin, Peoples R China

[2] Guangzhou Healthquest Pharm Co Ltd, Guangzhou, Peoples R China

[3] CAMS & PUMC, Inst Hematol & Blood Dis Hosp, State Key Lab Expt Hematol, Natl Clin Res Ctr Blood Dis,Haihe Lab Cell Ecosyst, Tianjin, Peoples R China

[4] Ascentage Pharma Suzhou Co Ltd, Suzhou, Peoples R China

[5] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Natl Clin Res Ctr Blood Dis, Dept Pediat Hematol & Oncol,State Key Lab Expt Hem, Tianjin, Peoples R China

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-207035

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1443 / 1444

页数：2

共 31 条

[21] Promising Safety and Efficacy Results from an Ongoing Phase 1b Study of Pembrolizumab Combined with Decitabine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Agrawal, Vaibhav
Croslin, Cindy
Beltran, Asuscena L.
Zhang, Jianying
Palmer, Joycelynne
Quy Huynh-Tran
Hernandez, Rochelle
Thomas, Sandra
Robbins, Marjorie
Aribi, Ahmed
Ali, Haris
Stein, Anthony S.
Budde, Elizabeth L.
Al Malki, Monzr M.
Marcucci, Guido
BLOOD, 2022, 140 : 6235 - 6236
[22] Imatinib combined with intensive HAM chemotherapy as consolidation of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph1-ALL). Preliminary results of the AFR03 phase I/II study.
Dombret, H
Witz, F
De Botton, S
Cayuela, JM
Delabesse, E
Preudhomme, C
Huguet-Rigal, F
Vekhoff, A
Dauriac, C
Hayette, S
Vey, N
Thomas, X
Kovacsovics, T
Delannoy, A
Ouslimani, A
Soler, E
Gabert, J
Macintyre, E
Vernant, JP
BLOOD, 2004, 104 (11) : 749A - 749A
[23] Successful treatment with chimeric antigen receptor (CAR) T-lymphocytes of an adult patient with relapsed and refractory (r/r) Philadelphia Chromosome (Ph) positive acute lymphoblastic leukemia (ALL) after allogeneic hematopoietic stem-cell transplantation (allo-HSCT) - a case report
Wegener, Sebastian
Hopfer, Olaf
Franke, Georg-Nikolaus
Jentzsch, Madlen
Kiehl, Michael
Platzbecker, Uwe
Vucinic, Vladan
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 147 - 147
[24] Safety and Pharmacokinetics of Subcutaneous Blinatumomab (SC blinatumomab) for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL); Results from a Phase 1b Study
Sanchez, Pilar Martinez
Zugmaier, Gerhard
Gordon, Paul
Jabbour, Elias
Roca, Jose J. Rifon
Schwartz, Stefan
Borlenghi, Erika
Huguet, Francoise
Hernandez-Rivas, Jesus Maria
Lussana, Federico
Berthon, Celine
Kadu, Priti
Wong, Hansen
Markovic, Ana
Katlinskaya, Yuliya
Rambaldi, Alessandro
BLOOD, 2022, 140 : 6122 - 6124
[25] An Update of Safety and Efficacy Results oiii Phase 1 Dose-Escalation and Expansion Study of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI), in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph plus ALL) Failing Prior TKI Therapies
Cortes, Jorge E.
Saikia, Tapan
Kim, Dong-Wook
Alvarado, Yesid
Nicolini, Franck E.
Rathnam, Krishnakumar
Khattry, Navin
Apperley, Jane F.
Deininger, Michael W.
de Lavallade, Hugues
Charbonnier, Aude
Granacher, Nikki
Gambacorti-Passerini, Carlo
Lucchesi, Alessandro
Mauro, Michael J.
Vandenberghe, Peter
Verhoef, Gregor
Whiteley, Andrew R.
Nag, Arijit
Radhakrishnan, Vivek S.
Apte, Shashikant
Yao, Siu-Long
Inamdar, Sandeep
Sreenivasan, Jayasree
Dillu, Ruchika Irene
Chimote, Geetanjali
BLOOD, 2021, 138
[26] ZUMA-4: A phase 1/2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in pediatric and adolescent subjects with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL).
Wayne, Alan S.
Sender, Leonard S.
Lee, Daniel Warnell
Handgretinger, Rupert
Brown, Patrick A.
Jiang, Yizhou
Navale, Lynn
Stout, Shanna
Aycock, Jeff
Wiezorek, Jeffrey S.
Jain, Rajul K.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[27] ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Shah, B.
Castro, J.
Goekbuget, N.
Kersten, M. Jose
Hagenbeek, T.
Wierda, W.
Schiller, G.
Bot, A.
Rossi, J. M.
Jiang, Y.
Navale, L.
Stout, S.
Aycock, J.
Wiezorek, J.
Jain, R.
ANNALS OF ONCOLOGY, 2016, 27
[28] A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10)
Wassmann, B
Gökbuget, N
Scheuring, UJ
Binckebanck, A
Reutzel, R
Gschaidmeier, H
Hoelzer, D
Ottmann, OG
ANNALS OF HEMATOLOGY, 2003, 82 (11) : 716 - 720
[29] A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10)
B. Wassmann
N. Gökbuget
U. J. Scheuring
A. Binckebanck
R. Reutzel
H. Gschaidmeier
D. Hoelzer
O. G. Ottmann
GMALL Study Group
Annals of Hematology, 2003, 82 : 716 - 720
[30] With up to 8 Years of Therapy, Asciminib (ASC) Monotherapy Demonstrated Continued Favorable Efficacy, Safety, and Tolerability in Patients (Pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph plus CML-CP) without the T315I Mutation: Final Results from the Phase 1 X2101 Study
Hochhaus, Andreas
Kim, Dong-Wook
Cortes, Jorge
Sasaki, Koji
Mauro, Michael
Hughes, Timothy P.
Breccia, Massimo
Talpaz, Moshe
Minami, Hironobu
Goh, Yeow Tee
DeAngelo, Daniel J.
Lang, Fabian
Heinrich, Michael C.
De Soria, Valle Gomez G.
le Coutre, Philipp
Sanchez-Olle, Gessami
Jose, Jomy
Pognan, Nathalie
Kapoor, Shruti
Rea, Delphine
BLOOD, 2023, 142

← 1 2 3 4 →